- Home
- HRYU vs EDSA Comparison
HRYU vs EDSA Comparison
Compare HRYU & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRYU
- EDSA
- Stock Information
- Founded
- HRYU 2018
- EDSA 2015
- Country
- HRYU South Korea
- EDSA Canada
- Employees
- HRYU N/A
- EDSA N/A
- Industry
- HRYU Computer Software: Programming Data Processing
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- HRYU Technology
- EDSA Health Care
- Exchange
- HRYU Nasdaq
- EDSA Nasdaq
- Market Cap
- HRYU 10.5M
- EDSA 11.0M
- IPO Year
- HRYU 2023
- EDSA N/A
- Fundamental
- Price
- HRYU $0.24
- EDSA $2.09
- Analyst Decision
- HRYU
- EDSA Strong Buy
- Analyst Count
- HRYU 0
- EDSA 1
- Target Price
- HRYU N/A
- EDSA $21.00
- AVG Volume (30 Days)
- HRYU 10.6M
- EDSA 50.3K
- Earning Date
- HRYU 11-26-2024
- EDSA 12-13-2024
- Dividend Yield
- HRYU N/A
- EDSA N/A
- EPS Growth
- HRYU N/A
- EDSA N/A
- EPS
- HRYU N/A
- EDSA N/A
- Revenue
- HRYU $528,595.00
- EDSA N/A
- Revenue This Year
- HRYU N/A
- EDSA N/A
- Revenue Next Year
- HRYU N/A
- EDSA N/A
- P/E Ratio
- HRYU N/A
- EDSA N/A
- Revenue Growth
- HRYU N/A
- EDSA N/A
- 52 Week Low
- HRYU $0.17
- EDSA $2.09
- 52 Week High
- HRYU $1.50
- EDSA $6.46
- Technical
- Relative Strength Index (RSI)
- HRYU 49.58
- EDSA 19.32
- Support Level
- HRYU $0.21
- EDSA $2.26
- Resistance Level
- HRYU $0.25
- EDSA $2.44
- Average True Range (ATR)
- HRYU 0.05
- EDSA 0.26
- MACD
- HRYU -0.00
- EDSA -0.06
- Stochastic Oscillator
- HRYU 23.62
- EDSA 0.00
About HRYU Hanryu Holdings Inc.
Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.